Mifepristone and Misoprostol Dose in Adults:

Risk Factor C (Monitor therapy)

Alosetron

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.

Androgens

May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.

Antidiabetic Agents

May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.

Benperidol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benperidol.

Betamethasone (Ophthalmic)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Betamethasone (Ophthalmic).

Bictegravir

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bictegravir.

Bortezomib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.

Bosentan

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

Bosentan

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosentan. Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.

Bosentan

CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan. Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.

Brentuximab Vedotin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.

Brinzolamide

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.

Budesonide (Nasal)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).

Budesonide (Oral Inhalation)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Oral Inhalation).

Calcifediol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Calcifediol.

Cannabidiol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabidiol.

Cannabis

CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased.

Cannabis

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased.

Carvedilol

CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.

Cinacalcet

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cinacalcet.

Clofazimine

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

CloZAPine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of CloZAPine. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.

Codeine

CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Codeine.

Corticosteroids (Orally Inhaled)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Orally inhaled fluticasone propionate with a strong CYP3A4 inhibitor is not recommended. Exceptions: Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).

CYP2B6 Substrates (High risk with Inhibitors)

MiFEPRIStone may increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).

CYP3A4 Inducers (Moderate)

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

CYP3A4 Inhibitors (Moderate)

May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).

Deferasirox

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

DexAMETHasone (Ophthalmic)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of DexAMETHasone (Ophthalmic).

Dexketoprofen

May diminish the therapeutic effect of MiFEPRIStone.

Digoxin

MiFEPRIStone may increase the serum concentration of Digoxin. Management: Measure serum digoxin concentration 1-2 weeks following mifepristone initiation, and in accordance with normal clinical practice thereafter, adjusting dose as needed.

Dofetilide

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dofetilide.

Doxercalciferol

CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Doxercalciferol.

Dronabinol

CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.

Dronabinol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol.

Dutasteride

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.

Enfortumab Vedotin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enfortumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.

Estrogen Derivatives

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Estrogen Derivatives.

Evogliptin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Evogliptin.

Fosnetupitant

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Fostamatinib

CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fostamatinib.

Galantamine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Galantamine.

Grapefruit Juice

May increase the serum concentration of MiFEPRIStone.

Herbs (Hypoglycemic Properties)

May enhance the hypoglycemic effect of HypoglycemiaAssociated Agents.

Hypoglycemia-Associated Agents

May enhance the hypoglycemic effect of other HypoglycemiaAssociated Agents.

Ifosfamide

CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.

Imatinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.

Imidafenacin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imidafenacin.

Lacosamide

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.

Levamlodipine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levamlodipine.

Levobupivacaine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.

Lornoxicam

CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam.

Lumefantrine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.

Maitake

May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.

Meperidine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Meperidine.

Monoamine Oxidase Inhibitors

May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.

Naldemedine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naldemedine.

Nalfurafine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nalfurafine.

Netupitant

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Ospemifene

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.

Oxybutynin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.

Parecoxib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Parecoxib.

Paricalcitol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.

Pegvisomant

May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.

Pimecrolimus

CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.

Polatuzumab Vedotin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Polatuzumab Vedotin. Exposure to unconjugated MMAE, the cytotoxic small molecule component of polatuzumab vedotin, may be increased.

Pranlukast

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.

Propafenone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.

Prothionamide

May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.

QT-prolonging Agents (Highest Risk)

QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.

Quinolones

May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.

Ramelteon

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ramelteon.

Repaglinide

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Repaglinide. Management: The addition of a CYP2C8 inhibitor to this drug combination may substantially increase the magnitude of increase in repaglinide exposure.

Retapamulin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin. Management: Avoid this combination in patients less than 2 years old. No action is required in other populations.

Rilpivirine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rilpivirine.

RomiDEPsin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.

Salicylates

May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.

Sarilumab

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

Selective Serotonin Reuptake Inhibitors

May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.

Sibutramine

CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Sibutramine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sibutramine.

Siltuximab

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

SORAfenib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.

Tasimelteon

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tasimelteon.

Tenoxicam

May diminish the therapeutic effect of MiFEPRIStone.

Tetrahydrocannabinol

CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol.

Tetrahydrocannabinol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol.

Tetrahydrocannabinol and Cannabidiol

CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. Specifically, concentrations of tetrahydrocannabinol may be increased.

Tetrahydrocannabinol and Cannabidiol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol.

Tocilizumab

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

TraMADol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of TraMADol.

Upadacitinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Upadacitinib.

Vilanterol

May increase the serum concentration of CYP3A4 Inhibitors (Strong).

Vindesine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vindesine.

Zolpidem

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zolpidem.

Risk Factor D (Consider therapy modification)

Abemaciclib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Abemaciclib. Management: In patients taking abemaciclib at a dose of 200 mg or 150 mg twice daily, reduce the dose to 100 mg twice daily when combined with strong CYP3A4 inhibitors. In patients taking abemaciclib 100 mg twice daily, decrease the dose to 50 mg twice daily.

Alitretinoin (Systemic)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic). Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP3A4 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP3A4 inhibitor.

Almotriptan

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan. Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.

ALPRAZolam

CYP3A4 Inhibitors (Strong) may increase the serum concentration of ALPRAZolam. Management: Consider using an alternative agent that is less likely to interact. If combined, monitor for increased therapeutic/toxic effects of alprazolam if combined with a strong CYP3A4 inhibitor.

ARIPiprazole

CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole. Management: See full interaction monograph for details.

ARIPiprazole Lauroxil

CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil. Management: Please refer to the full interaction monograph for details concerning the recommended dose adjustments.

Avatrombopag

MiFEPRIStone may increase the serum concentration of Avatrombopag. Management: Management of this interaction varies based on avatrombopag indication. Dose adjustments are required for patients using avatrombopag for chronic immune thrombocytopenia. See monograph for details.

Bedaquiline

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline. Management: Limit duration of concurrent use of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued use outweighs the possible risks. Monitor for toxic effects of bedaquiline. Exceptions discussed in separate monographs.

Brexpiprazole

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole. Management: Reduce brexpiprazole dose 50% with strong CYP3A4 inhibitors; reduce to 25% of usual if used with both a moderate CYP3A4 inhibitor and a CYP2D6 inhibitor in patients not being treated for MDD, or strong CYP3A4 inhibitor used in a CYP2D6 poor metabolizer.

Brigatinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brigatinib. Management: Avoid concurrent use of brigatinib with strong CYP3A4 inhibitors when possible. If combination cannot be avoided, reduce the brigatinib dose by approximately 50%, rounding to the nearest tablet strength (ie, from 180 mg to 90 mg, or from 90 mg to 60 mg).

Budesonide (Topical)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Topical). Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased.

BusPIRone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of BusPIRone. Management: Limit the buspirone dose to 2.5 mg daily and monitor patients for increased buspirone effects/toxicities if combined with strong CYP3A4 inhibitors.

Cabazitaxel

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel. Management: Concurrent use of cabazitaxel with strong inhibitors of CYP3A4 should be avoided when possible. If such a combination must be used, consider a 25% reduction in the cabazitaxel dose.

Cabozantinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib. Management: Avoid use of a strong CYP3A4 inhibitor with cabozantinib if possible. If combined, cabozantinib dose adjustments are recommended and vary based on the cabozantinib product used and the indication for use. See monograph for details.

Cariprazine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cariprazine. Management: Cariprazine dose reductions of 50% are required; specific recommended management varies slightly for those stable on cariprazine versus those just starting cariprazine. See prescribing information or full interaction monograph for details.

Ceritinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib. Management: If such combinations cannot be avoided, the ceritinib dose should be reduced by approximately one-third (to the nearest 150 mg). Resume the prior ceritinib dose after cessation of the strong CYP3A4 inhibitor. Exceptions discussed in separate monographs.

Cilostazol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving strong inhibitors of CYP3A4.

Colchicine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor. In those with normal renal and hepatic function, reduce colchicine dose as directed. See full monograph for details.

Conivaptan

May increase the serum concentration of MiFEPRIStone. Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 600 mg/day when combined with conivaptan. Monitor for increased mifepristone toxicity regardless of dose or indication.

Copanlisib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Copanlisib. Management: If concomitant use of copanlisib and strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg. Monitor patients for increased copanlisib effects/toxicities.

Crizotinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib. Management: Avoid concomitant use of crizotinib and strong CYP3A4 inhibitors whenever possible. If combined use cannot be avoided, decrease the crizotinib dose to 250 mg daily. Exceptions are discussed in separate monographs.

CYP2C9 Substrates (High risk with Inhibitors)

MiFEPRIStone may increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.

CYP3A4 Inhibitors (Strong)

May increase the serum concentration of MiFEPRIStone. Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 900 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.

CYP3A4 Substrates (High risk with Inhibitors)

MiFEPRIStone may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.

Daclatasvir

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Daclatasvir. Management: Decrease the daclatasvir dose to 30 mg once daily if combined with a strong CYP3A4 inhibitor. No dose adjustment is needed when daclatasvir is used with darunavir/cobicistat.

Dasatinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib. Management: This combination should be avoided if possible. If combined, dasatinib dose reductions are recommended. See full monograph for details. Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.

Delamanid

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Delamanid. Management: Increase ECG monitoring frequency if delamanid is combined with strong CYP3A4 inhibitors due to the risk for QTc interval prolongation. Continue frequent ECG assessments throughout full delamanid treatment period. Exceptions discussed separately.

Diclofenac (Systemic)

CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Diclofenac (Systemic). Management: Consider using a reduced dose of diclofenac when used together with moderate CYP2C9 inhibitors. Arthrotec (diclofenac and misoprostol) prescribing information recommends a maximum dose of 50 mg twice daily.

DOCEtaxel

CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOCEtaxel. Management: Avoid the concomitant use of docetaxel and strong CYP3A4 inhibitors when possible. If combined use is unavoidable, consider a 50% docetaxel dose reduction and monitor for increased docetaxel toxicities.

DOXOrubicin (Conventional)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional). Management: Seek alternatives to strong CYP3A4 inhibitors in patients treated with doxorubicin whenever possible. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.

Drospirenone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Drospirenone. Management: Drospirenone use is contraindicated specifically when the strong CYP3A4 inhibitors atazanavir and cobicistat are administered concurrently. Caution should be used when drospirenone is coadministered with other strong CYP3A4 inhibitors.

Duvelisib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Duvelisib. Management: Reduce the dose of duvelisib to 15 mg twice a day when used together with a strong CYP3A4 inhibitor.

Elagolix

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Elagolix. Management: Use of the elagolix 200 mg twice daily dose with a strong CYP3A4 inhibitor for longer than 1 month is not recommended. Limit combined use of the elagolix 150 mg once daily dose with a strong CYP3A4 inhibitor to a maximum of 6 months.

Eliglustat

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eliglustat. Management: Use should be avoided under some circumstances. See full drug interaction monograph for details.

Encorafenib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Encorafenib. Management: Avoid concomitant use of encorafenib and strong CYP3A4 inhibitors whenever possible. If concomitant administration is unavoidable, decrease the encorafenib dose. See monograph for details.

Entrectinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Entrectinib. Management: Avoid strong CYP3A4 inhibitors during treatment with entrectinib. Reduce dose to 100 mg/day if combination cannot be avoided in adults and those 12 yrs of age or older with a BSA of at least 1.5 square meters. No alternative dosing provided for others.

Erdafitinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erdafitinib. Management: Avoid concomitant use of erdafitinib and strong CYP3A4 inhibitors when possible. If combined, monitor closely for erdafitinib adverse reactions and consider dose modifications accordingly.

Erlotinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib. Management: Avoid use of this combination when possible. When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).

Estrogen Derivatives (Contraceptive)

MiFEPRIStone may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). MiFEPRIStone may increase the serum concentration of Estrogen Derivatives (Contraceptive). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.

Eszopiclone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eszopiclone. Management: Limit the eszopiclone dose to 2 mg daily when combined with strong CYP3A4 inhibitors and monitor for increased eszopiclone effects and toxicities (eg, somnolence, drowsiness, CNS depression).

Etizolam

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Etizolam. Management: Consider use of lower etizolam doses when using this combination; specific recommendations concerning dose adjustment are not available. Monitor clinical response to the combination closely.

Fedratinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fedratinib. Management: Consider alternatives when possible. If used together, decrease fedratinib dose to 200 mg/day. After the inhibitor is stopped, increase fedratinib to 300 mg/day for the first 2 weeks and then to 400 mg/day as tolerated.

Fesoterodine

CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine. Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.

Fluticasone (Oral Inhalation)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). Management: Use of orally inhaled fluticasone propionate with strong CYP3A4 inhibitors is not recommended. Use of orally inhaled fluticasone furoate with strong CYP3A4 inhibitors should be done with caution. Monitor patients using such a combination more closely.

Fluvastatin

MiFEPRIStone may increase the serum concentration of Fluvastatin. Management: Use fluvastatin at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.

Fosamprenavir

May increase the serum concentration of MiFEPRIStone. Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 600 mg/day when combined with fosamprenavir. Monitor for increased mifepristone toxicity regardless of dose or indication.

Gilteritinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gilteritinib. Management: Consider alternatives to the use of a strong CYP3A4 inhibitor with gilteritinib. If the combination cannot be avoided, monitor more closely for evidence of gilteritinib toxicities.

Glasdegib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Glasdegib. Management: Consider alternatives to this combination when possible. If the combination must be used, monitor closely for evidence of QT interval prolongation and other adverse reactions to glasdegib.

GuanFACINE

CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE. Management: Reduce the guanfacine dose by 50% when initiating this combination.

Iloperidone

CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.

Istradefylline

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Istradefylline. Management: Limit the maximum istradefylline dose to 20 mg daily when combined with strong CYP3A4 inhibitors and monitor for increased istradefylline effects/toxicities.

Ivacaftor

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor. Management: Ivacaftor dose reductions are required; consult full monograph content for productspecific recommendations.

Ivosidenib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivosidenib. Management: Avoid use of a strong CYP3A4 inhibitor with ivosidenib whenever possible. When combined use is required, reduce the ivosidenib dose to 250 mg once daily. Drugs listed as exceptions are discussed in further detail in separate drug interaction monographs.

Ixabepilone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.

Larotrectinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Larotrectinib. Management: Avoid use of strong CYP3A4 inhibitors with larotrectinib. If this combination cannot be avoided, reduce the larotrectinib dose by 50%. Increase to previous dose after stopping the inhibitor after a period of 3 to 5 times the inhibitor half-life.

Levomilnacipran

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran. Management: Do not exceed a maximum adult levomilnacipran dose of 80 mg/day in patients also receiving strong CYP3A4 inhibitors.

Lorlatinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lorlatinib. Management: Avoid use of lorlatinib with strong CYP3A4 inhibitors. If the combination cannot be avoided, reduce the lorlatinib dose from 100 mg once daily to 75 mg once daily, or from 75 mg once daily to 50 mg once daily.

Lorlatinib

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Avoid concurrent use of lorlatinib with any CYP3A4 substrates for which a minimal decrease in serum concentrations of the CYP3A4 substrate could lead to therapeutic failure and serious clinical consequences.

Manidipine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Manidipine. Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inhibitors. If combined, monitor closely for increased manidipine effects and toxicities. Manidipine dose reductions may be required.

Maraviroc

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc. Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor. Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.

Midostaurin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Midostaurin. Management: Seek alternatives to the concomitant use of midostaurin and strong CYP3A4 inhibitors if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions. Exceptions are discussed in separate monographs.

Mirodenafil

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirodenafil. Management: Consider using a lower dose of mirodenafil when used with strong CYP3A4 inhibitors. Monitor for increased mirodenafil effects/toxicities with the use of this combination.

Nilotinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib. Management: Avoid if possible. If combination needed, decrease nilotinib to 300 mg once/day for patients with resistant or intolerant Ph+ CML or to 200 mg once/day for patients with newly diagnosed Ph+ CML in chronic phase. Exceptions discussed in separate monograph.

Olaparib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Olaparib. Management: Avoid use of strong CYP3A4 inhibitors in patients being treated with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 100 mg twice daily.

OxyCODONE

CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.

Oxytocin

MiSOPROStol may enhance the adverse/toxic effect of Oxytocin. Specifically, oxytocic effects may be enhanced. Management: The manufacturer of misoprostol recommends avoiding concomitant use with oxytocin. Misoprostol may augment effects of oxytocin, particularly when given within 4 hours of oxytocin initiation.

Panobinostat

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat. Management: Reduce the panobinostat dose to 10 mg when it must be used with a strong CYP3A4 inhibitor.

PAZOPanib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of PAZOPanib. Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible. If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg. Further dose reductions may also be required.

Pexidartinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pexidartinib. Management: Avoid use of pexidartinib with strong CYP3A4 inhibitors if possible. If combined use cannot be avoided, the pexidartinib dose should be reduced. Decrease 800 mg or 600 mg daily doses to 200 mg twice daily. Decrease doses of 400 mg/day to 200 mg/day.

Pimavanserin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimavanserin. Management: Decrease the pimavanserin dose to 10 mg daily when combined with strong CYP3A4 inhibitors.

Piperaquine

CYP3A4 Inhibitors (Strong) may enhance the QTc-prolonging effect of Piperaquine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Piperaquine. Management: Avoid concomitant use of piperaquine and strong CYP3A4 inhibitors when possible. If the combination cannot be avoided, frequent ECG monitoring is recommended due to the risk for QTc prolongation. Exceptions are discussed separately.

PONATinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib. Management: Per ponatinib U.S. prescribing information, the adult starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.

Progestins (Contraceptive)

MiFEPRIStone may diminish the therapeutic effect of Progestins (Contraceptive). MiFEPRIStone may increase the serum concentration of Progestins (Contraceptive). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.

QUEtiapine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine. Management: In quetiapine treated patients, reduce quetiapine to one-sixth of regular dose after starting strong CYP3A4 inhibitor. In those on strong CYP3A4 inhibitors, start quetiapine at lowest dose and up-titrate as needed. Exceptions discussed separately.

Reboxetine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Reboxetine.

Ribociclib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ribociclib. Management: Avoid use of ribociclib with strong CYP3A4 inhibitors when possible; if combined use cannot be avoided, reduce ribociclib dose to 400 mg once daily. Exceptions are discussed in separate monographs.

Ruxolitinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib. Management: This combination should be avoided under some circumstances. See monograph for details.

SAXagliptin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin. Management: Limit the saxagliptin dose to 2.5 mg daily when combined with strong CYP3A4 inhibitors. When using the saxagliptin combination products saxagliptin/dapagliflozin or saxagliptin/dapagliflozin/metformin, avoid use with strong CYP3A4 inhibitors.

Sildenafil

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil. Management: Use of sildenafil for pulmonary hypertension should be avoided with strong CYP3A4 inhibitors. When used for erectile dysfunction, starting adult dose should be reduced to 25 mg. Maximum adult dose with ritonavir or cobicistat is 25 mg per 48 hours.

Solifenacin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Solifenacin. Management: Limit solifenacin doses to 5 mg daily when combined with strong CYP3A4 inhibitors.

Stiripentol

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity. Any CYP3A4 substrate used with stiripentol requires closer monitoring.

SUFentanil

CYP3A4 Inhibitors (Strong) may increase the serum concentration of SUFentanil. Management: If a strong CYP3A4 inhibitor is initiated in a patient on sufentanil, consider a sufentanil dose reduction and monitor for increased sufentanil effects and toxicities (eg, respiratory depression).

SUNItinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of SUNItinib. Management: Avoid when possible. If such a combination cannot be avoided, sunitinib dose decreases are recommended, and vary by indication. See full monograph for details.

Tadalafil

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil. Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.

Temsirolimus

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Temsirolimus. Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inhibitors whenever possible. If combined, decrease temsirolimus dose to 12.5 mg per week and monitor patients for increased temsirolimus effects and toxicities.

Tezacaftor

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tezacaftor. Management: When combined with strong CYP3A4 inhibitors, tezacaftor/ivacaftor should be administered in the morning, twice a week, approximately 3 to 4 days apart. No evening doses of ivacaftor alone should be administered.

Thiotepa

CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Thiotepa. Management: Thiotepa prescribing information recommends avoiding concomitant use of thiotepa and strong CYP3A4 inhibitors. If concomitant use is unavoidable, monitor for adverse effects and decreased efficacy.

Tofacitinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib. Management: Tofacitinib dose reductions are recommended when combined with strong CYP3A4 inhibitors. Recommended dose adjustments vary by tofacitinib formulation and therapeutic indication. See full monograph for details.

Tolterodine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine. Management: The maximum recommended adult dose of tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.

Toremifene

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene. Management: Use of toremifene with strong CYP3A4 inhibitors should be avoided if possible. If coadministration is necessary, monitor for increased toremifene toxicities, including QTc interval prolongation. Exceptions are discussed in separate monograph.

TraZODone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of TraZODone. Management: Consider the use of a lower trazodone dose and monitor for increased trazodone effects (eg, sedation, QTc prolongation) if combined with strong CYP3A4 inhibitors.

Valbenazine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Valbenazine. Management: Reduce the valbenazine dose to 40 mg daily when combined with strong CYP3A4 inhibitors.

Vardenafil

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil. Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. See full drug interaction monograph for details.

Vemurafenib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib. Management: Avoid concurrent use of vemurafenib with strong CYP3A4 inhibitors when possible. Consider use of an alternative that is not a strong inhibitor of CYP3A4 as clinically appropriate.

Venetoclax

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Venetoclax. Management: This combination is contraindicated during venetoclax initiation and ramp-up in patients with CLL/SLL. Reduced venetoclax doses are required during ramp-up for patients with AML, and reduced doses are required for all patients during maintenance therapy.

Vilazodone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. Management: Limit maximum adult vilazodone dose to 20 mg daily in patients receiving strong CYP3A4 inhibitors. The original vilazodone dose can be resumed following discontinuation of the strong CYP3A4 inhibitor.

Voxelotor

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Voxelotor. Management: Avoid concomitant use of voxelotor and strong CYP3A4 inhibitors. If concomitant use is unavoidable, reduce the voxelotor dose to 1,000 mg once daily.

Zanubrutinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zanubrutinib. Management: Decrease the zanubrutinib dose to 80 mg once daily during coadministration with a strong CYP3A4 inhibitor. Further dose adjustments may be required for zanubrutinib toxicities, refer to prescribing information for details.

Zopiclone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity if these agents are combined.

Zuclopenthixol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol. Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.

Risk Factor X (Avoid combination)

Acalabrutinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Acalabrutinib.

Ado-Trastuzumab Emtansine

CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.

Alfuzosin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.

Antacids

May enhance the adverse/toxic effect of MiSOPROStol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea. Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration). Exceptions: Aluminum Hydroxide; Calcium Carbonate; Potassium Bicarbonate; Sodium Bicarbonate.

Anticoagulants

MiFEPRIStone may enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.

Aprepitant

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Aprepitant.

Astemizole

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.

Asunaprevir

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir.

Avanafil

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.

Avapritinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avapritinib.

Axitinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib. Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible. If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.

Barnidipine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Barnidipine.

Blonanserin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Blonanserin.

Bosutinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.

Bromocriptine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bromocriptine.

Budesonide (Systemic)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic).

Carbetocin

MiSOPROStol may enhance the adverse/toxic effect of Carbetocin. Specifically, Carbetocin oxytocic effects may be enhanced.

Cobimetinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib.

Corticosteroids (Systemic)

MiFEPRIStone may diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.

CycloSPORINE (Systemic)

MiFEPRIStone may increase the serum concentration of CycloSPORINE (Systemic). Management: Avoid cyclosporine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.

CYP3A4 Inducers (Strong)

May decrease the serum concentration of MiFEPRIStone.

Dabrafenib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dabrafenib.

Dapoxetine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.

Dihydroergotamine

MiFEPRIStone may increase the serum concentration of Dihydroergotamine. Management: Avoid dihydroergotamine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.

Domperidone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.

Dronedarone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.

Eletriptan

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eletriptan.

Eplerenone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.

Ergotamine

MiFEPRIStone may increase the serum concentration of Ergotamine. Management: Avoid ergotamine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.

Everolimus

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.

FentaNYL

MiFEPRIStone may increase the serum concentration of FentaNYL. Management: Avoid fentanyl during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.

Flibanserin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Flibanserin.

Fluticasone (Nasal)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).

Fosaprepitant

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fosaprepitant.

Fusidic Acid (Systemic)

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Halofantrine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.

Ibrutinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ibrutinib. Management: Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term (eg, anti-infectives for 7 days or less), interrupt ibrutinib therapy until the strong CYP3A4 inhibitor is discontinued.

Idelalisib

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Irinotecan Products

CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan Products.

Isavuconazonium Sulfate

CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Strong) may increase isavuconazole serum concentrations. Management: Combined use is considered contraindicated per US labeling. Lopinavir/ritonavir (and possibly other uses of ritonavir doses less than 400 mg every 12 hours) is treated as a possible exception to this contraindication despite strongly inhibiting CYP3A4.

Ivabradine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.

Lapatinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib. Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib adult dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.

Lefamulin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lefamulin. Management: Avoid concomitant use of lefamulin tablets and strong inhibitors of CYP3A4.

Lemborexant

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lemborexant.

Lercanidipine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine.

Lomitapide

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.

Lovastatin

MiFEPRIStone may increase the serum concentration of Lovastatin. Management: Avoid lovastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.

Lumateperone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumateperone.

Lurasidone

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.

Macitentan

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.

Naloxegol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naloxegol.

Neratinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Neratinib.

NiMODipine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of NiMODipine.

Nisoldipine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.

Palbociclib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Palbociclib.

Phenylbutazone

May diminish the therapeutic effect of MiFEPRIStone. Management: Phenylbutazone should not be used for 8-12 days following mifepristone administration.

Pimozide

MiFEPRIStone may enhance the QTc-prolonging effect of Pimozide. MiFEPRIStone may increase the serum concentration of Pimozide. Management: Avoid pimozide during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.

QuiNIDine

MiFEPRIStone may enhance the QTc-prolonging effect of QuiNIDine. MiFEPRIStone may increase the serum concentration of QuiNIDine. Management: Avoid quinidine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.

Radotinib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Radotinib.

Ranolazine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.

Red Yeast Rice

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.

Regorafenib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.

Rupatadine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rupatadine.

Salmeterol

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.

Silodosin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.

Simeprevir

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simeprevir.

Simvastatin

MiFEPRIStone may increase the serum concentration of Simvastatin. Management: Avoid simvastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.

Siponimod

MiFEPRIStone may increase the serum concentration of Siponimod. Management: Coadministration of siponimod with miferpristone, a moderate inhibitor of CYP2C9 and a strong inhibitor of CYP3A4 is not recommended.

Sirolimus

MiFEPRIStone may increase the serum concentration of Sirolimus. Management: Avoid sirolimus during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.

Sonidegib

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sonidegib.

St John's Wort

May decrease the serum concentration of MiFEPRIStone.

Suvorexant

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.

Tacrolimus (Systemic)

MiFEPRIStone may enhance the QTc-prolonging effect of Tacrolimus (Systemic). MiFEPRIStone may increase the serum concentration of Tacrolimus (Systemic). Management: Avoid tacrolimus during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.

Tamsulosin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.

Terfenadine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Terfenadine. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.

Ticagrelor

CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.

Tolvaptan

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.

Trabectedin

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.

Triazolam

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triazolam.

Ubrogepant

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ubrogepant.

Udenafil

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Udenafil.

Ulipristal

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal. Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combo should be monitored for ulipristal toxicity.

VinCRIStine (Liposomal)

CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).

Vinflunine

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinflunine.

Vorapaxar

CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.